GW3965 hydrochloride No Further a Mystery
All enrolled people who been given no less than 1 dose of zosuquidar or placebo during induction were being monitored with the event of adverse activities (439 clients, 219 on zosuquidar and 210 on placebo). The commonest adverse events were relevant to the period of prolonged and major myelosuppression as is expected with induction chemotherapy. A